Researchers at CRC have evaluated the feasibility of in vivo PET study using 6-[18F]fluoro-m-tyrosine (6-[18F]FMT) on lesioned rats with 6-hydroxydopamine (6-OHDA), a rat model of Parkinson’s disease (PD).

The (6-[18F]FMT) is an effective PET tracer to evaluate DA terminals integrity and L-aromatic amino acid decarboxylase (AAAD) metabolic pathway.

Using this PET tracer, they were able to quantify loss of DA presynaptic function in unilaterally 6-OHDA lesioned rats.

Researchers are currently investigating this tracer in a longitudinal way to monitor the progression of dopaminergic dysfunction in more moderate and gradual preclinical PD models.

Contact [] us to discuss how these capabilities can forward your projects! We will help you develop tailored solutions.